Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?

Novo Nordisk has ceded market share in the fast-growing GLP‑1 weight‑loss market—losing ground to Eli Lilly’s tirzepatide products and lower‑cost compounded semaglutide sold via telehealth—sending its shares down roughly two‑thirds over the past 18 months; under a new CEO the company is moving aggressively to regain share by cutting self‑pay prices for FDA‑approved Ozempic and Wegovy to $349/month (from $499) and offering first‑time patients $199 for the first two doses (2mg Ozempic excluded), putting its pricing roughly on par with Lilly’s Zepbound and TrumpRx. Novo is also positioning for an expected FDA decision on an oral Wegovy tablet by year‑end and touting supply ahead of launch, a product that could broaden uptake and help reclaim patients from compounders, even as margin pressure increases in what the company and analysts see as an industry opportunity of up to ~$150 billion by 2035.

Analysis

Novo Nordisk has materially lost market share in the GLP-1 obesity/diabetes market to Eli Lilly’s tirzepatide products and lower-cost compounded semaglutide sold via telehealth, and its share price has declined roughly two-thirds over the past 18 months; the article notes Lilly’s revenue grew significantly faster than Novo’s over the past year. The 2022 shortage enabled compounding pharmacies and telehealth providers such as Hims & Hers to undercut branded pricing, and regulators have not eliminated compounded semaglutide from the market, prolonging competitive pressure.

Under its new CEO the company has moved to an aggressive pricing response: self-paying patients will now pay $349/month for FDA-approved Ozempic and Wegovy (down from $499) with first-time patients paying $199 for their first two doses (2mg Ozempic excluded), putting branded prices near parity with Lilly’s Zepbound and TrumpRx. Novo also briefly explored a partnership with telehealth providers under the prior CEO but shifted to price competition as the most direct tool to blunt compounder share gains.

Novo is positioning for an FDA decision on an oral Wegovy tablet by year-end and is touting supply ahead of launch; a pill form could enlarge the addressable market by converting injection users and regaining patients lost to compounders. The price cuts will likely compress margins in the near term, but management appears willing to trade margin for share in a market the company and analysts peg as a potential ~$150 billion opportunity by 2035; key risks are slower-than-expected patient migration back to branded drugs and continued compounded competition absent regulatory action.

Key Decisions for Investors

• Treat the FDA decision on the oral Wegovy pill (expected by year-end) as the primary near-term catalyst and consider incrementally adding to NVO on approval plus clear supply/launch guidance, since a pill could materially expand uptake and help reclaim share
• If approval is delayed or compounded semaglutide continues to hold share, consider trimming exposure or hedging positions because Novo’s price cuts to $349 from $499 and $199 introductory doses will pressure margins and may delay earnings recovery